悉尼圣文森特医院的心脏移植和VAD项目

Q2 Medicine
P. Macdonald
{"title":"悉尼圣文森特医院的心脏移植和VAD项目","authors":"P. Macdonald","doi":"10.1136/heartasia-2019-apahff.2","DOIUrl":null,"url":null,"abstract":"2018 marks the 50th anniversary of heart transplantation at St Vincent’s Hospital in Sydney. The modern era of heart transplantation for our institution commenced in 1984 and since then the programme has performed >1000 heart transplants (HTx), >1000 lung transplants and almost 100 combined heart-lung transplants. Bridge-to-transplant ventricular assist device (VAD) support began in 1994 with the pulsatile Heartmate 1 device with a transition to continuous flow VADs in the mid 2000s. Current activity is 20–25 VADs, 40–50 HTx and 50–60 lung transplants per year. Over the last 3 decades, there has been an increased utilisation of marginal donors including older DBD donors and more recently DCD donors.1 The latter has been facilitated by utilisation of normothermic machine perfusion (NMP) for donor heart retrieval and transport.2 Donor hearts retrieved using NMP now account for 20% of all HTx. This proportion is expected to increase in the future. There have also been major changes in recipient characteristics with increased referral of older patients with advanced heart failure. Assessment of physical frailty together with cognition and depression are now routine for all patients referred for HTx assessment.3 4 There has also been an increased reliance on bridge-to-transplant VAD to support patients to transplantation. Despite these changing donor and recipient characteristics, post-transplant survival remains excellent with a median survival of almost 15 years. HTx remains the most effective therapy for advanced heart failure but is limited by availability of suitable donors. Improvements in donor heart preservation are expected to further increase the availability of this life-saving therapy. References Dhital K, Iyer A, Connellan M, et al. Distant procurement orthotopic heart transplant from donation after circulatory death. Lancet 2015;385:2585–2591. Macdonald PS, Chew HC, Connellan M, Dhital K. Extracorporeal heart perfusion before heart transplantation: The heart in a box. Curr Opin Organ Transplant 2016;21:336–342. Jha S, Carter D, Hannu MK, et al. Frailty as a predictor of outcomes in transplant eligible patients with advanced heart failure. Transplantation 2016;100:429–436. Jha S, Carter D, Hannu MK, et al. Cognitive impairment improves the predictive validity of physical frailty for mortality in patients with advanced heart failure referred for heart transplantation. J Heart Lung Transplant 2016;35:1092–1100.","PeriodicalId":12858,"journal":{"name":"Heart Asia","volume":" ","pages":"A1 - A1"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/heartasia-2019-apahff.2","citationCount":"0","resultStr":"{\"title\":\"2 The heart transplant and VAD program at St Vincent’s hospital, sydney\",\"authors\":\"P. Macdonald\",\"doi\":\"10.1136/heartasia-2019-apahff.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"2018 marks the 50th anniversary of heart transplantation at St Vincent’s Hospital in Sydney. The modern era of heart transplantation for our institution commenced in 1984 and since then the programme has performed >1000 heart transplants (HTx), >1000 lung transplants and almost 100 combined heart-lung transplants. Bridge-to-transplant ventricular assist device (VAD) support began in 1994 with the pulsatile Heartmate 1 device with a transition to continuous flow VADs in the mid 2000s. Current activity is 20–25 VADs, 40–50 HTx and 50–60 lung transplants per year. Over the last 3 decades, there has been an increased utilisation of marginal donors including older DBD donors and more recently DCD donors.1 The latter has been facilitated by utilisation of normothermic machine perfusion (NMP) for donor heart retrieval and transport.2 Donor hearts retrieved using NMP now account for 20% of all HTx. This proportion is expected to increase in the future. There have also been major changes in recipient characteristics with increased referral of older patients with advanced heart failure. Assessment of physical frailty together with cognition and depression are now routine for all patients referred for HTx assessment.3 4 There has also been an increased reliance on bridge-to-transplant VAD to support patients to transplantation. Despite these changing donor and recipient characteristics, post-transplant survival remains excellent with a median survival of almost 15 years. HTx remains the most effective therapy for advanced heart failure but is limited by availability of suitable donors. Improvements in donor heart preservation are expected to further increase the availability of this life-saving therapy. References Dhital K, Iyer A, Connellan M, et al. Distant procurement orthotopic heart transplant from donation after circulatory death. Lancet 2015;385:2585–2591. Macdonald PS, Chew HC, Connellan M, Dhital K. Extracorporeal heart perfusion before heart transplantation: The heart in a box. Curr Opin Organ Transplant 2016;21:336–342. Jha S, Carter D, Hannu MK, et al. Frailty as a predictor of outcomes in transplant eligible patients with advanced heart failure. Transplantation 2016;100:429–436. Jha S, Carter D, Hannu MK, et al. Cognitive impairment improves the predictive validity of physical frailty for mortality in patients with advanced heart failure referred for heart transplantation. J Heart Lung Transplant 2016;35:1092–1100.\",\"PeriodicalId\":12858,\"journal\":{\"name\":\"Heart Asia\",\"volume\":\" \",\"pages\":\"A1 - A1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1136/heartasia-2019-apahff.2\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart Asia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/heartasia-2019-apahff.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/heartasia-2019-apahff.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

2018年是悉尼圣文森特医院心脏移植50周年。我们机构的现代心脏移植始于1984年,从那时起,该项目已经进行了1000多次心脏移植(HTx) 肺移植和近100例心肺联合移植。桥接移植心室辅助装置(VAD)支持始于1994年,Heartmate 1型脉动装置于2000年代中期过渡到连续流VAD。目前的活动是每年20–25个VAD、40–50个HTx和50–60个肺移植。在过去的30年里,边缘供体的利用率有所提高,包括老年DBD供体和最近的DCD供体。1后者通过利用常温机器灌注(NMP)进行供体心脏取回和运输而得到促进。2使用NMP取回的供体心脏现在占所有HTx的20%。这一比例预计在未来还会增加。随着老年晚期心力衰竭患者转诊的增加,受体特征也发生了重大变化。现在,对所有接受HTx评估的患者,身体虚弱以及认知和抑郁的评估都是常规的。3 4也越来越依赖桥接移植VAD来支持患者进行移植。尽管供体和受体的特征发生了变化,但移植后的存活率仍然很高,中位存活率几乎为15年。HTx仍然是治疗晚期心力衰竭最有效的方法,但受到合适供体的限制。供体心脏保存的改善有望进一步增加这种挽救生命的疗法的可用性。参考文献Dhital K,Iyer A,Connellan M等。循环系统死亡后从捐赠中远程获得原位心脏移植。《柳叶刀》2015;385:2585–2591。Macdonald PS,Chew HC,Connellan M,Dhital K.心脏移植前体外心脏灌注:盒子里的心脏。Curr Opin器官移植2016;21:336–342。Jha S,Carter D,Hannu MK等人。虚弱是符合移植条件的晚期心力衰竭患者预后的预测因素。移植2016;100:429–436。Jha S,Carter D,Hannu MK等人。认知障碍提高了身体虚弱对心脏移植晚期心力衰竭患者死亡率的预测有效性。《心肺移植杂志》2016;35:1092–1100。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
2 The heart transplant and VAD program at St Vincent’s hospital, sydney
2018 marks the 50th anniversary of heart transplantation at St Vincent’s Hospital in Sydney. The modern era of heart transplantation for our institution commenced in 1984 and since then the programme has performed >1000 heart transplants (HTx), >1000 lung transplants and almost 100 combined heart-lung transplants. Bridge-to-transplant ventricular assist device (VAD) support began in 1994 with the pulsatile Heartmate 1 device with a transition to continuous flow VADs in the mid 2000s. Current activity is 20–25 VADs, 40–50 HTx and 50–60 lung transplants per year. Over the last 3 decades, there has been an increased utilisation of marginal donors including older DBD donors and more recently DCD donors.1 The latter has been facilitated by utilisation of normothermic machine perfusion (NMP) for donor heart retrieval and transport.2 Donor hearts retrieved using NMP now account for 20% of all HTx. This proportion is expected to increase in the future. There have also been major changes in recipient characteristics with increased referral of older patients with advanced heart failure. Assessment of physical frailty together with cognition and depression are now routine for all patients referred for HTx assessment.3 4 There has also been an increased reliance on bridge-to-transplant VAD to support patients to transplantation. Despite these changing donor and recipient characteristics, post-transplant survival remains excellent with a median survival of almost 15 years. HTx remains the most effective therapy for advanced heart failure but is limited by availability of suitable donors. Improvements in donor heart preservation are expected to further increase the availability of this life-saving therapy. References Dhital K, Iyer A, Connellan M, et al. Distant procurement orthotopic heart transplant from donation after circulatory death. Lancet 2015;385:2585–2591. Macdonald PS, Chew HC, Connellan M, Dhital K. Extracorporeal heart perfusion before heart transplantation: The heart in a box. Curr Opin Organ Transplant 2016;21:336–342. Jha S, Carter D, Hannu MK, et al. Frailty as a predictor of outcomes in transplant eligible patients with advanced heart failure. Transplantation 2016;100:429–436. Jha S, Carter D, Hannu MK, et al. Cognitive impairment improves the predictive validity of physical frailty for mortality in patients with advanced heart failure referred for heart transplantation. J Heart Lung Transplant 2016;35:1092–1100.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Heart Asia
Heart Asia Medicine-Cardiology and Cardiovascular Medicine
CiteScore
2.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信